TITLE

ImaRx Halts Phase I/II SonoLysis Stroke Trial Due to Bleeding

AUTHOR(S)
Morrison, Trista
PUB. DATE
January 2008
SOURCE
BioWorld Today;1/7/2008, Vol. 19 Issue 4, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of ImaRx Therapeutics Inc. to close its Phase I/II stroke trial due to an increase in intracranial hemorrhage events in patients MRX-801 microbubbles combined with ultrasound and tissue-plasminogen activator (tPA). Chief medical officer Garen Manvelian said tPA is known to cause bleeding and the affect could have been multiplied by adding MRX-801. TPA triggers an enzyme cascade that dissolves blood clots but increases hemorrhage risks.
ACCESSION #
28123824

 

Related Articles

  • ImaRx halts stroke study, but data backs follow-on research. Yoffee, Lynn // Medical Device Daily;1/7/2008, Vol. 12 Issue 4, p1 

    The article reports on the hurdle facing ImaRx Therapeutics in relation to the development of a therapy for ischemic stroke. The company demonstrated that patients can recover from ischemic stroke with its SonoLysis therapy combined with ultrasound. However, because an undisclosed number of...

  • 'Too many failures' limiting the push for new stroke drugs. MORRISON, TRISTA // Cardiovascular Devices & Drugs;Apr2009, Vol. 15 Issue 4, p3 

    The article offers a look at the failed results of various clinical trials on stroke drugs. Warren Wasiewski, vice president and chief medical officer of Neurobiological Technologies, revealed that there have been many failures in new drug development for stroke. Such failed trials include...

  • Product pipeline.  // Cardiovascular Device Update;Oct2007, Vol. 13 Issue 10, p33 

    The article reports on the approval received by Tucson, Arizona-based ImaRx Therapeutics from the data and safety monitoring board to proceed with the second dose cohort in its Transcranial Ultrasound in Clinical SONoLysis (TUCSON) Phase I/II dose escalation study evaluating SonoLysis + tPA...

  • ImaRx, Philips develop microbubble technology for ischemic stroke. Yoffee, Lynn // Cardiovascular Device Update;Nov2007, Vol. 13 Issue 11, p25 

    This article reports on a research alliance announced by ImaRx Therapeutics and Royal Philips Electronics in 2007 that focused on using Philip's ultrasound technology. Under the alliance, the technology will be part of the SonoLysis program of ImaRx to develop a treatment for acute ischemic...

  • IMARX INITIATES TRIALS FOR NON-INVASIVE BLOOD CLOT TREATMENT.  // Biotech Equipment Update;Nov2003, p6 

    ImaRx Therapeutics Inc. in Tucson, Arizona, has initiated clinical trials to investigate the use of the company's SonoLysis Technology for the treatment of blood clots in kidney dialysis patients whose access grafts have become blocked. ImaRx's unique SonoLysis technique combines the use of...

  • Tucson's ImaRx launches new oxygen treatments for shock.  // Inside Tucson Business;7/18/2005, Vol. 15 Issue 5, p3 

    Reports on the launch of a NanO2 Nanobubble Therapeutics programs designed to deliver portable emergency oxygen treatment to patients with hemorrhagic shock by Tucson-based ImaRx Therapeutics Inc. Potential applications of Nan02 therapeutics; Development of the program around ImaRx's existing...

  • ImaRX receives NIH grant for blood/brain barrier study.  // Cardiovascular Device Update;Sep2007, Vol. 13 Issue 9, p21 

    The article announces that the National Institute of Neurological Disorders and Stroke gave a $950,000 research grant to ImaRX Therapeutics.

  • ImaRx Halts Phase I/II SonoLysis Stroke Trial.  // Bioworld Week;1/14/2008, Vol. 16 Issue 2, p2 

    The article reports on the early closure by ImaRx Therapeutics Inc. in Tucson, Arizona, of its Phase I/II stroke trial. It states that it was stopped after it was found that there was an increase in intracranial hemorrhages in patients when they received MRX-801 microbubbles with ultrasound and...

  • REvamped ImaRx in hunt for venture capital. Rademacher, Kevin // Inside Tucson Business;12/11/200, Vol. 10 Issue 38, p1 

    Reports on Tucson, Arizona-based biotechnology firm ImaRx Therapeutics' search for venture capital. Business activity; Firms that have given financial backing.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics